GlassScriptPhysician profile
Ihab Ibrahim Soliman
NPI 1851594212
$93,422.60
in general payments reported to CMS, 2019-2025
26 companies · $22K in 2025
The $22K reported for 2025 was more than what 98% of Child & Adolescent Psychiatry providers received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,925 · 2020: $5,023 · 2021: $6,829 · 2022: $16K · 2023: $26K · 2024: $13K · 2025: $22K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $28K · Honoraria: $20K · Food and Beverage: $7,734 · Travel and Lodging: $4,180.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $28,280.00 |
| Honoraria | $20,425.00 |
| Food and Beverage | $7,733.96 |
| Travel and Lodging | $4,179.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $62,623.06 | 2022-2025 | Qelbree, Qelbree |
| Ironshore Pharmaceuticals INC. | $23,336.81 | 2019-2024 | Jornay Pm |
| Tris Pharma INC | $1,451.68 | 2019-2025 | Dyanavel Xr, Onyda Xr, Quillichew Er |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,038.59 | 2020-2025 | Caplyta |
| Abbvie INC. | $857.67 | 2021-2025 | Vraylar |
| Alkermes, INC. | $745.68 | 2023-2025 | Aristada, Lybalvi |
| Corium, LLC | $738.28 | 2023-2025 | Azstarys |
| Allergan, INC. | $483.62 | 2019-2020 | |
| Bausch Health US, LLC | $343.10 | 2019-2025 | Aplenzin, Wellbutrin |
| Sunovion Pharmaceuticals INC. | $271.35 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $268.79 | 2019-2025 | Rexulti |
| Lundbeck LLC | $212.50 | 2019-2025 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $172.91 | 2024-2025 | Cobenfy |
| Neos Therapeutics, LP | $156.20 | 2019-2025 | Adzenys Xr-Odt |
| Takeda Pharmaceuticals U.S.A., INC. | $115.80 | 2019-2024 | Trintellix |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertical Pharmaceuticals, LLC | $109.12 | 2019 | |
| Vanda Pharmaceuticals INC. | $102.43 | 2020-2025 | Fanapt, Hetlioz |
| Arbor Pharmaceuticals, INC. | $71.45 | 2019-2020 | |
| Collegium Pharmaceutical, INC. | $57.23 | 2025 | Jornay Pm |
| Idorsia Pharmaceuticals US INC | $48.37 | 2023-2024 | Quviviq |
| Axsome Therapeutics, INC. | $47.33 | 2023 | Sunosi, Auvelity |
| Almatica Pharma LLC | $46.37 | 2025 | Loreev Xr |
| Adlon Therapeutics L.P. | $45.70 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $44.11 | 2019 | |
| Neuronetics, INC. | $20.06 | 2019 | |
| Dentsply Sirona INC | $14.39 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ihab Soliman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.